Elekta: Growing from the Head Down
Executive Summary
Elekta established its reputation with the Leksell Gamma Knife for neurosurgery. Now, after a turnaround, it is expanding into a comprehensive cancer care company.
You may also be interested in...
TomoTherapy: Niche Player or Not?
Radiation oncology is a very attractive market indeed. It's a $3 billion-plus capital equipment market predicted to experience a compound annual growth rate of 10 to 15% in the next several years, with the image-guided segment expected to grow at a 35% rate. Approximately 30% of the market is up for grabs over the next three years, as institutions replace old and obsolete equipment. Can small company TomoTherapy sustain the lead it has gained with a new image-guided system that increases the precision of cancer targeting and spares normal tissues, once entrenched multi-billion dollar radiation oncology companies begin to offer aggressive competition?
Accuray: Building the Radiosurgery Market
Building a new product market is never easy, and the chances for a start-up in capital equipment are especially slim. Accuray has the scars to prove it. But after a long haul, it appears to be succeeding in building a market in radiosurgery.
Accuray: Building the Radiosurgery Market
Building a new product market is never easy, and the chances for a start-up in capital equipment are especially slim. Accuray has the scars to prove it. But after a long haul, it appears to be succeeding in building a market in radiosurgery.